Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups.

Journal: Urologic oncology
Published Date: Oct 1, 2015

Abstract

OBJECTIVES: Recent studies showed that robot-assisted radical prostatectomy (RARP) represents an oncologically safe procedure in patients with prostate cancer (PCa), where the rate of positive surgical margins (PSMs) might be lower in patients treated with RARP as compared with that of those undergoing the open approach (open RP [ORP]). The aim of this study is to analyze the rate of PSMs according to preoperative risk groups in a large cohort of patients treated with RARP and ORP in a single institution with standardized surgical technique and pathological examination.

Authors

  • Nazareno Suardi
    Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: suardi.nazareno@hsr.it.
  • Paolo Dell'Oglio
    Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
  • Andrea Gallina
    Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Giorgio Gandaglia
    Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.
  • Nicolò Buffi
    Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
  • Marco Moschini
    Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Nicola Fossati
    Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Giovanni Lughezzani
    Humanitas Clinical and Research Center-IRCCS, Department of Urology, Rozzano, Italy.
  • Pierre I Karakiewicz
    Sami-Ramzi Leyh-Bannurah, Dirk Pehrke, Hartwig Huland, Markus Graefen, and Lars Budäus, Prostate Cancer Center Hamburg-Eppendorf; Sami-Ramzi Leyh-Bannurah, Margit Fisch, and Guido Sauter, University Medical Center Hamburg-Eppendorf, Hamburg; Ulrich Wolffgang, University of Muenster, Muenster, Germany; and Zhe Tian and Pierre I. Karakiewicz, University of Montreal Health Center, Montreal, Canada.
  • Massimo Freschi
    Division of Oncology/Unit of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Roberta Lucianò
    Division of Oncology/Unit of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Shahrokh F Shariat
    Department of Urology, Medical University of Vienna and General Hospital, Vienna, Austria.
  • Giorgio Guazzoni
    Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
  • Franco Gaboardi
    Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Francesco Montorsi
    Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.
  • Alberto Briganti
    Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.

Keywords

External Resources

Popular Topics
Recent Journals